OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sullivan on Targeted Therapy for BRAF-Mutant Melanoma

February 20th 2018

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses novel molecular targets in patients with melanoma.

Dr. Koontz on Next Steps for Study of LHRH in Prostate Cancer

February 20th 2018

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses the next steps for the phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer

February 20th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses challenges with immunotherapy in bladder cancer.

Dr. Wang on Results With Crenolanib Plus Chemotherapy in AML

February 20th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the results of the combination of crenolanib plus chemotherapy in a study of patients with acute myeloid leukemia.

Dr. Goy on Acalabrutinib Versus Ibrutinib in MCL

February 20th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) in the treatment of patients with mantle cell lymphoma.

Dr. Andre Discusses the Future of Immunotherapy in mCRC

February 20th 2018

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the future of immunotherapy for patients with metastatic colorectal cancer.

Dr. Salgia on Crizotinib and Other TKIs in ALK-Positive NSCLC

February 19th 2018

Ravi Salgia, MD, PhD, associate director, Clinical Sciences Research, Arthur & Rosalie Kaplan Chair, Medical Oncology, professor and chair, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses effective agents in the treatment of patients with ALK-positive tumors.

Dr. Schwartz on the Results of the PACIFIC Trial

February 19th 2018

Gary Schwartz, MD, Baylor Scott & White Center for Thoracic Surgery, discusses the potential of single-agent durvalumab (Imfinzi) for the treatment of patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC).

Dr. Shiller on the Challenges in the Development of NSCLC Biomarkers

February 17th 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses the difficulties that are preventing a more streamlined approached in testing for biomarkers.

Dr. Mason on the Intersection of Surgery and Biomarkers in NSCLC

February 17th 2018

David P. Mason, MD, Baylor Scott & White Center for Thoracic Surgery, discusses a case that demonstrates the evolution of lung cancer surgery in a biomarker-driven era.

Dr. Crane on Combinations With PARP Inhibitors in Ovarian Cancer

February 17th 2018

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses combinations with PARP inhibitors in ovarian cancer.

Dr. Traina Discusses Neratinib in HER2+ Breast Cancer

February 17th 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Dr. Gulley on Take Home Message With Olaparib Plus Durvalumab in mCRPC

February 17th 2018

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service at the National Cancer Institute, discusses the take-home message with the combination of olaparib (Lynparza) plus durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer.

Dr. Patel on the FDA Approval of Durvalumab in NSCLC

February 17th 2018

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

Dr. Stinchcombe on the KEYNOTE-189 Trial in Lung Cancer

February 17th 2018

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the KEYNOTE-189 trial in patients with lung cancer.

Dr. Arend on Novel Combination Strategies in Gynecologic Cancer

February 17th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses novel combination strategies in gynecologic cancer.

Dr. Bardia on the Role of the Microenvironment in TNBC

February 17th 2018

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses the role of the microenvironment in the treatment of metastatic triple-negative breast cancer (TNBC).

Dr. Lagunes on the Importance of Developing More Personalized Treatments in NETs

February 16th 2018

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the necessity of tailored approaches in the treatment of patients with neuroendocrine tumors (NETs).

Dr. Perl Discusses the Impact of CAR T-Cell Therapy on ALL

February 16th 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with acute lymphoblastic leukemia (ALL).

Dr. Sonpavde on Immunotherapy Combination Studies in Urothelial Carcinoma

February 16th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses immunotherapy combination studies for the treatment of patients with urothelial carcinoma.